Close  

References

  1. Aranesp® product monograph. AMGEN® Canada Inc., 2002.
  2. Eschbach JW. Anemia in chronic renal failure. In: Johnson RJ, Feehally J. Comprehensive Clinical Nephrology. London, UK: Harcourt Publishers Ltd. 2000.
  3. Murphy ST, Parfrey PS. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Sem Nephrol 2000;20(4):350-355.
  4. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34(1):125-134.
  5. Johnson RJ, Feehally J. Comprehensive Clinical Nephrology. London, UK: Harcourt Publishers Ltd. 2000.
  6. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990;38:480-486
  7. Levin A. Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies. Nephrol Dial Transplant 1999;14:292-295
  8. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989;14:14-18.
  9. Toffelmire EB, Barrett BJ, Fenton SS, Ferguson B, Halligan P. Clinical Practice Guidelines for the Management of Anemia coexistent with Chronic Renal Failure. J Am Soc Nephrol 1999;10:S292-S296
  10. Eprex® product monograph. Janssen-Ortho Inc., 2003.
  11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001;37(suppl 1):S182-S238.
  12. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60;741-747.
  13. Clyne N, Jogestrand T. Effect of erythropoietin treatment of physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992;60:390-396.
  14. Lote CJ. Principles of renal physiology. 4th ed. The Netherlands: Kluwer Academic Publishers, 2000.
  15. Eschbach JW, Cook JD, Scribner BH. Iron balance in hemodialysis patients. J Ann Int Med 1977;87:710-713.
  16. The Annals of Pharmacotherapy. January 1996;30:96-103.
  17. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20(4):375-381.
  18. Tsakiris D. Morbidity and mortality reduction associated with the use of erythropoietin. Nephron 2000;85(1):2-8.
  19. Nissenson AR. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001;38(6):1390-7.
  20. National Kidney Foundation. Dialysis Outcomes Quality Initiative (DOQI): Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York, NY: National Kidney Foundation. 1997.
  21. Compendium of pharmaceuticals and specialties (CPS) (36th edition). Canadian Pharmacists' Association, 2001.
  22. Lazarus JM, Denker BM, Owen WF. Hemodialysis. In: BM Brenner, & FC Rector (Eds.), The Kidney (4th edition) (p. 2458). Philadelphia: WB Saunders Company.
  23. Remuzzi G, Rossi C. Hematologic consequences of renal failure. In: BM Brenner, & FC Rector (Eds.), The Kidney (4th edition) (p.2170). Philadelphia: WB Saunders Company.
  24. Hebel S, ed. Drug facts and comparisons 2000. St. Louis, MO: Facts and comparisons. 2000.
  25. Johnson C. Use of androgens in patients with renal failure. Semin Dial 2000;13:36-39.
  26. Macdougall IC. Metabolic adjuvants to erythropoietin therapy. Miner Electrolyte Metab 1999;25:357-364.
  27. Eschbach JW. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythroepoietin. Kidney Int 1989;35:134-148.
  28. Crosby E, Ferguson D, Hume HA, et al. Guidelines for red blood cell and plasma transfusion for adults and children. CMAJ 1997;156(11):S1.
  29. Circular of Information for the Use of Human Blood and Blood Components. American Association of Blood Banks, 2000.
  30. Sautner T, Gruenberger T, Barlan M et al. Immunological risk factors are solely responsible for primary non-function of renal allografts. Transpl Int. 1994;7(1):S294-7.
  31. Koene R, Hoitsma A. Evaluation of renal transplant donor and recipient. In: Johnson RJ, Feehally J. Comprehensive Clinical Nephrology. London, UK: Harcourt Publishers Ltd. 2000.
  32. Mydlik M, Derziova K, Zemberova E. Metabolism of B6 and its requirements in chronic renal failure. Kidney Int 1997;51:S56-S59.
  33. Golper T. L-carnitine administration to hemodialysis patients: has its time come? Semin Dial 1992;5:94-98.
  34. Bazilinski N. Carnitine: an overview. In J Artif Organs 1990;13:720-722.
  35. Horl W. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999;14:50-60.
  36. McEyoy GK, (Ed.) AHFS Drug Information 2000. Bethesda, MD: American Society of Health-System Pharmacists, 2000.